Updated Jul 16, 2026
Anzalone Christopher Richard is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $13.16M.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2025-12-16 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | S — Open-market sale | 3.2K | $67.87 | $219K |
| 2025-12-16 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | S — Open-market sale | 166 | $66.77 | $11K |
| 2025-12-16 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | S — Open-market sale | 1.3K | $65.77 | $86K |
| 2025-12-16 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | S — Open-market sale | 1.0K | $64.96 | $65K |
| 2025-12-16 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | S — Open-market sale | 6.7K | $64.29 | $428K |
| 2025-12-16 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | S — Open-market sale | 8.5K | $62.94 | $533K |
| 2025-12-16 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | S — Open-market sale | 14.1K | $62.12 | $876K |
| 2025-12-16 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | S — Open-market sale | 11.0K | $61.25 | $671K |
| 2025-12-16 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | S — Open-market sale | 8.4K | $60.51 | $509K |
| 2025-12-16 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | S — Open-market sale | 8.1K | $69.96 | $570K |
| 2025-12-16 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | S — Open-market sale | 21.3K | $69.28 | $1.48M |
| 2025-12-16 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | S — Open-market sale | 100.5K | $68.67 | $6.90M |
| 2025-12-16 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | A — Grant or award | 180.0K | $0.00 | |
| 2024-12-23 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 12.6K | $19.59 | $246K |
| 2024-12-20 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | A — Grant or award [10b5-1] | 100.0K | $0.00 | |
| 2024-12-20 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 5.8K | $22.12 | $128K |
| 2024-12-20 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 8.3K | $21.74 | $180K |
| 2024-12-20 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 12.7K | $20.52 | $260K |
Anzalone Christopher Richard is a corporate insider — currently tracked as Chief Executive Officer, Director. InsiderAlpha tracks every SEC Form 4 filing in real time.
Recorded transactions: 0 open-market purchases () and 16 open-market sales ($13.16M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Anzalone Christopher Richard profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.